Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation
Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation
Neutropenia is very common in patients received hematopoietic stem cell transplantation, with
 median duration of about 14 days. Almost all neutropenia will suffer from febrile without
 prophylactic antibiotics. IDSA recommended fluoroquinolones as prophylaxis in neutropenia
 patients of high risks, while in China, major pathogens possess high resistance to
 fluoroquinolones. It is not clear whether prophylaxis is of benefit, nor the appropriate
 prophylaxis regimen.

 The current study will evaluate the three different regimen:

 1. No prophylaxic antibiotic

 2. Piperacillin as prophylaxis for neutropenia patients. Piperacillin has anti-pseudomonas
 activity.

 3. Piperacillin/tazobactam as prophylaxis for neutropenia patients. Piperacillin/tazobactam
 has highest susceptibility rate among common anti-pseudomonas antibiotics.
1. Swab culture (skin, pharyngeal, nasal, anus) when administered into laminar flow room
 after transplantation.

 2. Randomize the neutropenia patients into 3 groups.

 3. Receive 3 regimen.

 4. Full record of clinical data, including background diseases, previous antibiotics within
 90 days, febrile or not at the TOC.

 5. For patients developed febrile, imipenem will be prescribed, even if the patient
 received no prophylaxis. At the same time, the follow-up ended.
Inclusion Criteria:

 -  Age 13-65 years

 -  Received Autologous or Allogeneic hematopoietic stem cell transplantation.

 -  ECOG score 0-1.

 -  ICF is available.

 Exclusion Criteria:

 -  Allergic to any therapy drug.

 -  Documented infection before neutropenia.

 -  Renal dysfunction.

 -  Suffering from central nervous system or mental disease.